Patients with non-GCB DLBCL and PD-L1 expression are approximately 17% less likely to survive after 5 years than those without PD-L1 expression.

News

Patients with mantle cell lymphoma (MCL) should be stratified based on the status of a specific mutation and considered for alternative first-line therapy, according to a new study published in Blood (online August 18, 2017; doi:10.1182/blood-2017-04-779736).

-----

Related Content

Read More

A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma (DLBCL).

-----

Related Content

Read More

Obinutuzumab may improve survival and lower the risk of worsening disease compared with rituximab in patients with follicular lymphoma, according to results from the phase 3 GALLIUM study. 

Read More

A study comparing seven prophylaxis strategies for reducing the risk of febrile neutropenia (FN) in patients with non-Hodgkin lymphoma receiving chemotherapy found that routine primary prophylaxis (PP) with nivestim or pegfilgrastim is cost-effective. 

Read More

Research in Review

Findings from a single-center analysis have shown that anthracycline-based therapies may produce better outcomes in patients age 80 years and older with diffuse large B-cell lymphoma (DLBCL), supporting data reported in previous clinical trials.

Read More

Using positron emission tomography (PET) imaging to guide chemotherapy may help to improve progression-free survival (PFS) for patients with advanced Hodgkin lymphoma (HL), according to a study conducted by the Southwest Oncology Group, Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium.

Read More

Subscribe to Leukemia & Lymphoma